MedTrace Logo

Home Blood Pressure Monitoring and Blood Pressure Control

NCT00202137 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 597

Last updated 2016-01-14

No results posted yet for this study

Summary

Hypertension is a common problem in Canada with a prevalence of about 15%. The goal of hypertension therapy should be to maximize blood pressure control. Home blood pressure monitoring (HBPM) devices are available and many patients are using them. The role that self-monitoring of blood pressure can play in optimizing blood pressure control is unclear. We hope to clarify the role of home blood pressure monitoring in the treatment of hypertension and explore how it may affect patient and physician behaviours related to blood pressure management. This study will compare a group of hypertensive patients who use HBPM with those who do not use these devices. The intervention (HBPM) group will measure their blood pressure at home a minimum of once weekly and will report these measurements to their family doctor at each visit. The control group will receive usual care as delivered by their family doctor. Outcomes of blood pressure control will be measured over a 12 month period. Outcomes will be determined primarily by 24 hour ambulatory blood pressure monitoring and by reviewing data in patient's charts located in family physicians office. Fifty family physicians from the Kingston area have agreed to participate.

Conditions

Interventions

BEHAVIORAL

Home blood pressure monitoring

Monitor blood pressure using home blood pressure monitor

BEHAVIORAL

Physician monitoring of blood pressure

Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)

Sponsors & Collaborators

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Queen's University

    lead OTHER

Principal Investigators

  • Marshall Godwin, MD MSc · Queen's University, Kingston, Ontario, Canada

  • Richard Birtwhistle, MD MSc · Queen's University, Kingston, Ontario, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2007-04-30
Completion
2007-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202137 on ClinicalTrials.gov